Axovant Sciences (AXON) IPO Prices at Top End of Range

Axovant Sciences Ltd. (NYSE: AXON) priced its initial public offering of 21,000,000 common shares at a price of $15 per share, the high end of the expected $13-$15 range. Shares are expected to begin trading today on the NYSE under the symbol "AXON."

All of the common shares are being offered by Axovant Sciences Ltd. In addition, Axovant Sciences Ltd. has granted the underwriters a 30-day option to purchase up to 3,150,000 additional common shares.

Jefferies LLC, Evercore Group L.L.C. and RBC Capital Markets LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager, and Robert W. Baird & Co. Incorporated is acting as co-manager for the offering.

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia, a condition characterized by significant decline in mental capacity and impaired daily function.

You May Also Be Interested In

• The West Can't Process Enough of This Critical Metal, and the Gap Doesn't Close by 2030
• Karman Line Acquisition closes $200M IPO on Nasdaq
• SpaceX held talks to acquire AI coding startup Cognition - report